On August 6, 2026, breast cancer support organizations in Australia highlighted the importance of endocrine therapy compliance in hormone-receptor-positive breast cancers. Sourcing authentic treatments like V-Strant (Fulvestrant) 250mg PFS is vital for patients requiring selective estrogen receptor downregulators.

At Onco Medicine, we specialize in verified cold-chain shipping of hormone therapies to Australia, supporting patients and oncology clinics with original products and complete customs compliance.

Endocrine Therapy and Fulvestrant Action

Fulvestrant is an estrogen receptor antagonist that targets hormone-receptor-positive (HR+) breast cancers in postmenopausal women:

• Estrogen Receptor Degradation: Binds to estrogen receptors on cancer cells, promoting receptor degradation and shutting down the estrogen pathways driving tumor cell division.
• Pre-Filled Syringe Convenience: The 250mg/5mL pre-filled syringe (PFS) ensures exact dosing and sterile clinical administration.
• Dosing Protocol: Administered as two 250mg intramuscular injections (one in each buttock) on days 1, 15, and 29, and once monthly thereafter.

Australia TGA Personal Importation Guidelines

Under the Therapeutic Goods Administration (TGA) Personal Importation Scheme, Australian residents can legally import essential cancer therapies:

• Australian Doctor Prescription: A prescription from an Australian-registered oncologist or general practitioner is mandatory.
• Importation Limits: Maximum 3-month supply per shipment, and a total of 15 months' supply per calendar year.
• Documents Pack: Every shipment must carry a copy of the prescription, commercial invoice, and manufacturer COA on the parcel exterior to guarantee smooth customs entry.

Onco Medicinecoordinates specialized 2–8°C cold-chain logistics to deliver V-Strant directly to clinics and residences in Sydney, Melbourne, Brisbane, and Adelaide.